Millie
your market intelligence analyst
Search Results
14 results
Your search is now limited to «Roche» expert search.
Your search is now limited to only one Source. To return to results from all sources click here.
Pharmafile 11/11/2019 08:03
You studied biology at Liverpool John Moores University before heading straight to GSK in 1990 as a Sales Representative; was a career in pharma always the plan? No it wasn’t. I studied biology at John Moores, specialising in plant Pathology, so I was initially interested in horticulture. I’d grown up in a farming community, so I quickly worked out, after a placement year working for the Ministry of Agriculture, that the part I really loved was going out and engaging with the farmers, setting up trials in their fields, and working with the community.
Pharmafile 10/21/2019 04:52
New Phase 3 data has emerged demonstrating the efficacy of Roche’s Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) in the treatment of unresectable hepatocellular carcinoma (HCC) in patients who have not received prior systemic therapy. The results, drawn from a trial of 501 unresectable HCC patients, showed that the pair of drugs met the trial’s co-primary endpoints, generating "statistically significant and clinically meaningful improvements" in both overall survival and progression-free survival compared to Nexavar (sorafenib), the current standard of care.
Pharmafile 10/01/2019 05:36
Roche has revealed data from an interim analysis of its immunotherapy Tecentriq (atezolizumab) at the 2019 European Society for Medical Oncology (ESMO) congress, showing promising performance in combination with platinum-based chemotherapy in the first-line treatment of previously untreated locally advanced or metastatic urothelial carcinoma (mUC) eligible and ineligible for cisplatin chemotherapy. The Tecentriq combo demonstrated a "statistically significant improvement" in progression-free survival (PFS) of 8.2 months compared to 6.3 months with chemotherapy alone.
Pharmafile 08/30/2019 07:22
Roche has announced the approval of Tecentriq (atezolizumab), in combination with Celgene’s chemotherapy drug Abraxane (nab paclitaxel), by the European Medicines Agency in the treatment of PD-L1-positive, unresectable locally advanced or metastatic triple-negative breast cancer, making it the first immunotherapy regimen available in the continent for this indication.

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications